© 4	n 1440A/PTO & 1440B/PI	<u> </u>		r		1-4-184	e==::::=						
THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known										
			Application Number 10/088,639										
			Filing Date March 20, 2002					-4 -1					
			First Named Inventor Thomas Brodin e										
	(use as many shee	ets es necessas) P	<u> </u>	Examiner Name Larry Ronald Hel					lms				
Sheet	1of		10	Attorney Docket Number 003300-920				<u> </u>	<u> </u>				
		APR 1	म आफ ह	PATENT DOCUM	ENTS		-	-					
Examiner Initials	Document Number	Kind Teria (if known)	RAURHA	Name of Pat of Cite	entee or Applican d Document	t			Issue/P (MM	ublica			
						•							
							·						
			·										
			FOREIG	SN PATENT DOCU	IMENTS								
T T			1	<del></del>				ST	ATUS			······	
Examiner Initials	Document Number	Kind Code (if known)		Country	Date of Publication (MM-DD-YYY		Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Spec	
									ļ				
					<del></del>			ļ	ļ	-	_	<u> </u>	
	<del></del>				+	-	-			-	<del> </del>	+-	
			<del> </del>	r			1		<del> </del>	+	-	┼─	
		·	<del></del>		<del></del>		<del> </del>	<del> </del>	+	+	├	+	

NON-PATENT LITERATURE DOCUMENTS						
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
PKT	Oxford Dictionary of Biochemistry and Molecular Biology, 1997, p. 165, Oxford University Press, New York.					
PKT	DOHLSTEN et al., "Monoclonal antibody-superantigen fusion proteins: Tumor-specific agents for T-cell based tumor therapy", Proc. Natl. Acad. Sci. USA, September, 1994, Vol. 91, pp. 8945-8949, Pharmacia Oncology Immunology, Lund, Sweden					

Examiner	•	Date	
Examine	/- 1.8 8	Date	1 12/00/2006
Ciannetura	/Parithosh K Tungaturthi/	Considered	12/08/2006
Signature	/Parichosh & Tungacurchi/	Considered	, 55, -555

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.